Recurrent Glioblastoma—Molecular Underpinnings and Evolving Treatment Paradigms
Glioblastoma is the most common and lethal central nervous system malignancy with a median survival after progression of only 6–9 months. Major biochemical mechanisms implicated in glioblastoma recurrence include aberrant molecular pathways, a recurrence-inducing tumor microenvironment, an...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Published: |
MDPI AG
2024
|
| Online Access: | https://hdl.handle.net/1721.1/155435 |
| _version_ | 1826209233047126016 |
|---|---|
| author | Chang, Christopher Chavarro, Velina S. Gerstl, Jakob V. E. Blitz, Sarah E. Spanehl, Lennard Dubinski, Daniel Valdes, Pablo A. Tran, Lily N. Gupta, Saksham Esposito, Luisa Mazzetti, Debora Gessler, Florian A. Arnaout, Omar Smith, Timothy R. Friedman, Gregory K. Peruzzi, Pierpaolo Bernstock, Joshua D. |
| author2 | Koch Institute for Integrative Cancer Research at MIT |
| author_facet | Koch Institute for Integrative Cancer Research at MIT Chang, Christopher Chavarro, Velina S. Gerstl, Jakob V. E. Blitz, Sarah E. Spanehl, Lennard Dubinski, Daniel Valdes, Pablo A. Tran, Lily N. Gupta, Saksham Esposito, Luisa Mazzetti, Debora Gessler, Florian A. Arnaout, Omar Smith, Timothy R. Friedman, Gregory K. Peruzzi, Pierpaolo Bernstock, Joshua D. |
| author_sort | Chang, Christopher |
| collection | MIT |
| description | Glioblastoma is the most common and lethal central nervous system malignancy with a median survival after progression of only 6–9 months. Major biochemical mechanisms implicated in glioblastoma recurrence include aberrant molecular pathways, a recurrence-inducing tumor microenvironment, and epigenetic modifications. Contemporary standard-of-care (surgery, radiation, chemotherapy, and tumor treating fields) helps to control the primary tumor but rarely prevents relapse. Cytoreductive treatment such as surgery has shown benefits in recurrent glioblastoma; however, its use remains controversial. Several innovative treatments are emerging for recurrent glioblastoma, including checkpoint inhibitors, chimeric antigen receptor T cell therapy, oncolytic virotherapy, nanoparticle delivery, laser interstitial thermal therapy, and photodynamic therapy. This review seeks to provide readers with an overview of (1) recent discoveries in the molecular basis of recurrence; (2) the role of surgery in treating recurrence; and (3) novel treatment paradigms emerging for recurrent glioblastoma. |
| first_indexed | 2024-09-23T14:19:18Z |
| format | Article |
| id | mit-1721.1/155435 |
| institution | Massachusetts Institute of Technology |
| last_indexed | 2025-02-19T04:23:26Z |
| publishDate | 2024 |
| publisher | MDPI AG |
| record_format | dspace |
| spelling | mit-1721.1/1554352025-02-04T02:18:15Z Recurrent Glioblastoma—Molecular Underpinnings and Evolving Treatment Paradigms Chang, Christopher Chavarro, Velina S. Gerstl, Jakob V. E. Blitz, Sarah E. Spanehl, Lennard Dubinski, Daniel Valdes, Pablo A. Tran, Lily N. Gupta, Saksham Esposito, Luisa Mazzetti, Debora Gessler, Florian A. Arnaout, Omar Smith, Timothy R. Friedman, Gregory K. Peruzzi, Pierpaolo Bernstock, Joshua D. Koch Institute for Integrative Cancer Research at MIT Glioblastoma is the most common and lethal central nervous system malignancy with a median survival after progression of only 6–9 months. Major biochemical mechanisms implicated in glioblastoma recurrence include aberrant molecular pathways, a recurrence-inducing tumor microenvironment, and epigenetic modifications. Contemporary standard-of-care (surgery, radiation, chemotherapy, and tumor treating fields) helps to control the primary tumor but rarely prevents relapse. Cytoreductive treatment such as surgery has shown benefits in recurrent glioblastoma; however, its use remains controversial. Several innovative treatments are emerging for recurrent glioblastoma, including checkpoint inhibitors, chimeric antigen receptor T cell therapy, oncolytic virotherapy, nanoparticle delivery, laser interstitial thermal therapy, and photodynamic therapy. This review seeks to provide readers with an overview of (1) recent discoveries in the molecular basis of recurrence; (2) the role of surgery in treating recurrence; and (3) novel treatment paradigms emerging for recurrent glioblastoma. 2024-06-28T20:48:45Z 2024-06-28T20:48:45Z 2024-06-19 2024-06-26T13:23:01Z Article http://purl.org/eprint/type/JournalArticle 1422-0067 https://hdl.handle.net/1721.1/155435 Chang, C.; Chavarro, V.S.; Gerstl, J.V.E.; Blitz, S.E.; Spanehl, L.; Dubinski, D.; Valdes, P.A.; Tran, L.N.; Gupta, S.; Esposito, L.; et al. Recurrent Glioblastoma—Molecular Underpinnings and Evolving Treatment Paradigms. Int. J. Mol. Sci. 2024, 25, 6733. PUBLISHER_CC 10.3390/ijms25126733 International Journal of Molecular Sciences Creative Commons Attribution https://creativecommons.org/licenses/by/4.0/ application/pdf MDPI AG Multidisciplinary Digital Publishing Institute |
| spellingShingle | Chang, Christopher Chavarro, Velina S. Gerstl, Jakob V. E. Blitz, Sarah E. Spanehl, Lennard Dubinski, Daniel Valdes, Pablo A. Tran, Lily N. Gupta, Saksham Esposito, Luisa Mazzetti, Debora Gessler, Florian A. Arnaout, Omar Smith, Timothy R. Friedman, Gregory K. Peruzzi, Pierpaolo Bernstock, Joshua D. Recurrent Glioblastoma—Molecular Underpinnings and Evolving Treatment Paradigms |
| title | Recurrent Glioblastoma—Molecular Underpinnings and Evolving Treatment Paradigms |
| title_full | Recurrent Glioblastoma—Molecular Underpinnings and Evolving Treatment Paradigms |
| title_fullStr | Recurrent Glioblastoma—Molecular Underpinnings and Evolving Treatment Paradigms |
| title_full_unstemmed | Recurrent Glioblastoma—Molecular Underpinnings and Evolving Treatment Paradigms |
| title_short | Recurrent Glioblastoma—Molecular Underpinnings and Evolving Treatment Paradigms |
| title_sort | recurrent glioblastoma molecular underpinnings and evolving treatment paradigms |
| url | https://hdl.handle.net/1721.1/155435 |
| work_keys_str_mv | AT changchristopher recurrentglioblastomamolecularunderpinningsandevolvingtreatmentparadigms AT chavarrovelinas recurrentglioblastomamolecularunderpinningsandevolvingtreatmentparadigms AT gerstljakobve recurrentglioblastomamolecularunderpinningsandevolvingtreatmentparadigms AT blitzsarahe recurrentglioblastomamolecularunderpinningsandevolvingtreatmentparadigms AT spanehllennard recurrentglioblastomamolecularunderpinningsandevolvingtreatmentparadigms AT dubinskidaniel recurrentglioblastomamolecularunderpinningsandevolvingtreatmentparadigms AT valdespabloa recurrentglioblastomamolecularunderpinningsandevolvingtreatmentparadigms AT tranlilyn recurrentglioblastomamolecularunderpinningsandevolvingtreatmentparadigms AT guptasaksham recurrentglioblastomamolecularunderpinningsandevolvingtreatmentparadigms AT espositoluisa recurrentglioblastomamolecularunderpinningsandevolvingtreatmentparadigms AT mazzettidebora recurrentglioblastomamolecularunderpinningsandevolvingtreatmentparadigms AT gesslerfloriana recurrentglioblastomamolecularunderpinningsandevolvingtreatmentparadigms AT arnaoutomar recurrentglioblastomamolecularunderpinningsandevolvingtreatmentparadigms AT smithtimothyr recurrentglioblastomamolecularunderpinningsandevolvingtreatmentparadigms AT friedmangregoryk recurrentglioblastomamolecularunderpinningsandevolvingtreatmentparadigms AT peruzzipierpaolo recurrentglioblastomamolecularunderpinningsandevolvingtreatmentparadigms AT bernstockjoshuad recurrentglioblastomamolecularunderpinningsandevolvingtreatmentparadigms |